



ESBRA

CONGRESS 2017

8-11 OCTOBER 2017



CRETA MARIS
CONVENTION CENTRE

HERSONISSOS
CRETE / GREECE



22 European CME credits by the
European Accreditation Council for
Continuing Medical Education



Secretariat: Panhellas Tourism & Congress

ESBRA CRETE 2017 SCIENTIFIC PROGRAM

8TH - 11TH OCTOBER

PAGES

3. WELCOME ADDRESS

4. OVERVIEW SCIENTIFIC PROGRAM

5. SUNDAY 8TH OCTOBER, 2017

6. MONDAY 9TH OCTOBER, 2017

8. TUESDAY 10TH OCTOBER, 2017

10. WEDNESDAY 11TH OCTOBER, 2017

11. SCIENTIFIC PROGRAM

12. SUNDAY 8TH OCTOBER, 2017

14. MONDAY 9TH OCTOBER, 2017

19. TUESDAY 10TH OCTOBER, 2017

24. WEDNESDAY 11TH OCTOBER, 2017

25. PLENARY

33. POSTERS

SCIENTIFIC COMMITTEE

TOMÁŠ ZIMA

HELMUT SEITZ

MARCIN WOJNAR

JOAQUIN FERNANDEZ-SOLA

FÉLIX STICKEL

GIOVANNI ADDOLORATO

PHILIPPE DEWITTE

ESA KORPI

MICKAËL NAASSILA

HENRIETTE WALTER

ROBERTA WARD

GIANCARLO COLOMBO

JONATHAN CHICK

ORGANIZING COMMITTEE

ANIFANTAKIS, JANNIS (FLORENCE)

CHRISTIDI, STELLA (ATHENS)

DIAKOGIANNIS, IOANNIS (THESSALONIKI)

FOTOPOULOS, DIMOS (RETHYMNO)

GRINAKIS, EVANGELOS (HERAKLION)

KOGEVINAS, ANTHONY (CORFU)

KOULENTAKI, MARY (HERAKLION)

LESCH, OTTO (VIENNA)

MELLOS, ELEFThERIOS (ATHENS)

PANAGIOTIDIS, PANAGIOTIS (THESSALONIKI)

PANAGIS, GEORGIOS (RETHYMNO)


PAPARRIGOPOULOS, THOMAS (ATHENS)

TÖZÜN, NURDAN (ISTANBUL)

TOTEVA, SONIA (SOFIA)

TZANAKIS, NIKOS (HERAKLION)

VERESIES, KYRIACOS (LARNACA)



welcome address

Dear Colleagues,

On behalf of the Organizing Committee of the ESBRA 2017 Congress I am happy to welcome you to the 16th Congress of the European Society for Biomedical Research on Alcoholism in Heraklion, Crete. The congress takes place in Hersonissos, at the Convention Center Creta Maris, 30 kilometers from the city of Heraklion.

ESBRA, a society that promotes excellence in alcohol research on a European and international level, has a precious tradition of scientific meetings. The organizing committee aims to follow this rich tradition offering outstanding new scientific information on animal and human experimental studies, epidemiology, psychological and social aspects, groups of mutual help and, of course, clinical practice in the large and developing scientific field of Alcoholology.

During the ESBRA 2017 Congress leading scientists in their field will give state-of-the-art lectures in seven plenary sessions. We will have the opportunity to be informed on recent developments in the fields of epidemiology and genetics, association between alcohol and cancer, alcoholism subgroups, fetal alcohol spectrum disorders, alcohol use disorders in special populations, alcoholic liver disease and pharmacological treatment among others.

There will be 24 symposia covering issues on recent knowledge about prevention, treatment, social and psychological aspects of alcohol use disorders, as well as basic and clinical aspects of alcohol related pathologies. Among them there are joint symposia of ESBRA with LASBRA (Latin-American Society for Biomedical Research on Alcoholism), ISBRA (International Society for Biomedical Research on Alcoholism), European Association for the Study of Liver (EASL) and Japanese Medical Society of Alcohol and Addiction Studies (JMSAAS).

Finally, for the 16th ESBRA Congress there have been selected and will be presented 18 free oral communications and 50 posters. Four educational and interactive workshops have been organized.

The congress aspires to be an ideal place for researchers, clinicians, and students to interact and share ideas. The Organizing Committee of the ESBRA 2017 Congress expects to offer a platform for building European and worldwide collaborations and networks in the field of Alcoholology. In the spirit of the above principles we hope to offer to you a friendly milieu that will encourage the ignition of innovative ideas.

Dear Colleagues, enjoy the Congress!

Iannis A. Mouzas
Congress President, ESBRA 2017



ESBRA CRETE 2017 SCIENTIFIC PROGRAM

OVERVIEW SCIENTIFIC PROGRAM

OCTOBER

SUNDAY 8TH

MONDAY 9TH

TUESDAY 10TH

WEDNESDAY 11TH

SUNDAY 8TH OCTOBER, 2017**10:00 - 13:30 Registrations - Olympus Hall**

11:00 - 13:00

ESBRA Board Meeting 1

APHRODITE HALL

13:00 - 14:30

**FREE ORAL COMMUNICATIONS
PRECLINICAL-CNS-PSYCHOSOCIAL**

DANAE HALL

Chairs: Roberta Ward, Belgium/UK
Consuelo Guerri, Spain**FREE ORAL COMMUNICATIONS
EPIDEMIOLOGY-PSYCHOSOCIAL**

ATHENA HALL

Chairs: Sonya Toteva, Bulgaria
Marcin Wojnar, Poland

14:30 - 15:30

PLENARY1 Chair: Esa Korpi, Finland
**Ethanol's interaction with brain dopamine systems
provides clues for new treatments of alcoholism**
Bo Söderpalm, Sweden

15:30 - 16:00

COFFEE TO GO

16:00 - 17:30

**S01 Alcoholic fatty liver: Pathology and
screening strategies**

MINOS HALL

Chairs: Sebastian Mueller, Germany,
Claus Hellerbrand, Germany**S02 Acute and chronic effects of ethanol on
ligand-gated ion channels**

DANAE HALL

Chairs: Luis G. Aguayo, Chile,
Mia Ericson, Sweden**WORKSHOP 1**

ATHENA HALL

Human error, medical error and how they are builtAnthony Kogevinas, Greece
Nurdan Tözün, Turkey

17:30 - 18:30

PLENARY2 Chair: Iannis Mouzas, Greece
**Pharmacological treatment of alcoholic
patients: a focus on GABA_B-ergic drugs**
Giovanni Addolorato, Italy

18:30 - 19:30

**OPENING CEREMONY / WELCOME SPEECHES
OPENING SPEECH****Spinalonga, a monument of outstanding universal value**
Nick Panoutsopoulos, archaeologist

19:30

**Exhibition opening & Get together
welcome reception - ALCOHOL FREE COCKTAILS**

MONDAY 9TH OCTOBER, 2017

08:30 - 10:00

S03 Investigation of vulnerability to addictive behavior in animal models of alcohol use disorder

MINOS HALL

Chair: Mickael Naassila, France

S04 Role of iron in alcoholic liver disease: Molecular insights and prognostic aspects

DANAE HALL

Chairs: Sebastian Mueller, Germany,
Carolin Lackner, Austria**WORKSHOP 2**

ATHENA HALL

Lesch Typology: How to use it in daily practice

Otto Lesch, Austria

10:00 - 10:30

COFFEE TO GO

10:30 - 11:30

PLENARY3 Chair: Helmut Seitz, Germany

Alcohol and Cancer: From epidemiology to genetic susceptibility and animal models

Vasilis Vasiliou, USA

11:30 - 13:00

S05 Drinking to cope or coping not to drink - managing emotions in alcohol dependence

MINOS HALL

Chairs: Marcin Wojnar, Poland
Kirk J. Brower, USA**S06 Modifiers of progression of alcoholic liver disease**

DANAE HALL

Chairs: Claus Hellerbrand, Germany
Felix Stickel, Switzerland**S07 Treatment of alcohol dependence with agonistic substances**

ATHENA HALL

Chairs: Albrecht Ulmer, Germany
Icro Maremmani, Italy

13:00 - 14:00

LUNCH BREAK

14:00 - 14:30

Poster Session I

14:30 - 15:30

PLENARY4 Chair: Jonathan Chick

Alcohol misuse in special populations; learning disabilities and people with traumatic brain injury.

Christos Kouimtsidis, UK

MONDAY 9TH OCTOBER, 2017

15:30 - 17:00

S08 Clinically relevant research in subgroups of alcoholism

MINOS HALL

Chairs: Roberta Ward, UK/Belgium
Henriette Walter, Austria**S09 Role of Nutrition in Alcoholic Liver Disease**

DANAE HALL

Chairs: Irina A. Kirpich, USA
Samir Zakhari, USA**S10 Why do repeated alcohol detoxifications matter?**

ATHENA HALL

Chairs: Christos Kouimtsidis, UK
Theodora Duka, UK

17:00 - 17:30

COFFEE TO GO

17:30 - 19:00

S11 Novel G protein-coupled receptors as potential targets for treating alcoholism

MINOS HALL

Chair: Esa Korpi, Finland

S12 Possibilities and pitfalls in mutual help for alcohol problems

DANAE HALL

Chair: Jonathan Chick, UK

S23 Alcohol and cancer

ATHENA HALL

Chairs: Vasilis Vasiliou, USA
Helmut K. Seitz, Germany

19:00 - 20:30

ESBRA General Assembly

DANAE HALL

TUESDAY 10TH OCTOBER, 2017

<p>08:30 - 10:00</p>	<p>S13 Challenges in the treatment of alcoholic liver disease (Symposium organized by the Hellenic Association for the Study of the Liver) Chair: Evangelos Akriviades, Greece</p> <p>S14 New approaches for understanding alcohol use disorders and potential new treatments (ESBRA-LASBRA Joint Symposium) Chairs: Rosana Camarini, Brazil Mickael Naassila, France</p> <p>WORKSHOP 3 Benefits of hypnotherapy against craving? Henriette Walter, Austria</p>	<p>MINOS HALL</p> <p>DANAE HALL</p> <p>ATHENA HALL</p>
<p>10:00 - 10:30</p>	<p>COFFEE TO GO</p>	
<p>10:30 - 11:30</p>	<p>PLENARY5 Chair: Giovanni Addolorato Subgroups of addiction: From basic research to therapy Otto Lesch, Austria</p>	
<p>11:30 - 13:00</p>	<p>S15 New insights into adolescent binge drinking: Preclinical and clinical studies Chairs: Consuelo Guerri, Spain, Rosana Camarini, Brasil</p> <p>S16 Alcoholic Fatty Liver Disease: Use of animal and cell models for identification of potential novel therapeutic targets and implications of alcohol-therapeutic interactions Chairs: Carol A. Casey, USA Min You, USA</p> <p>S17 Alcohol use disorders in the General Hospital Chairs: Ioannis Diakogiannis, Greece Panagiotis Panagiotidis, Greece</p>	<p>MINOS HALL</p> <p>DANAE HALL</p> <p>ATHENA HALL</p>
<p>13:00 - 14:00</p>	<p>LUNCH BREAK</p>	
<p>14:00 - 14:30</p>	<p>Poster Session II</p> <p>ESBRA BOARD MEETING II</p>	
<p>14:30 - 15:30</p>	<p>PLENARY6 Chair: Consuelo Guerri Fetal Alcohol Spectrum Disorders (FASD). An overview Edward P. Riley, USA</p>	

TUESDAY 10TH OCTOBER, 2017

15:30 - 17:00

S18 Joint EASL-ESBRA symposium
New molecular insight leads to new therapeutic concepts

MINOS HALL

Chairs: Pau Sancho-Bru (EASL)
 Felix Stickel (ESBRA)

S19 Alcohol use disorders in Greece:
Clinical and treatment issues

DANAE HALL

Chairs: Thomas Paparrigopoulos,
 Dimos Fotopoulos

S20 Alcohol potentiates the pathogenesis of viral infections

ATHENA HALL

Chairs: Kusum K. Kharbanda, USA
 Natalia A. Osna USA

16:00 - 17:00

COFFEE TO GO

17:00 - 18:00

Charles Lieber Memorial Lecture Chair: Tomáš Zima
Alcohol Intake: From Initiation to Relapse Binge-drinking. Mechanisms and Translational Opportunities

Yedi Israel, Chile

18:00 - 19:30

S21 Comorbidities of alcohol dependence
JMSAAS/ESBRA joint symposium

MINOS HALL

Chairs: Toshi Saito, Japan
 Helmut K. Seitz, Germany

S22 YOUNG INVESTIGATOR SYMPOSIUM

DANAE HALL

Chairs: Tomáš Zima, Czech Republic
 Iannis Mouzas, Greece

WORKSHOP 4

ATHENA HALL

Cognitive behavioral treatment in alcohol use disorders. A user guide

Christos Kouimtsidis, UK

20:30

Departure by coach in front of the Creta Maris Convention Centre

Evening including dinner arrangements and a Folklore show in a Cretan Village

Return to the hotel around Midnight

WEDNESDAY 11TH OCTOBER, 2017

08:30 - 10:00

**FREE ORAL COMMUNICATIONS
ALCOHOL INDUCED ORGANIC DAMAGE**

MINOS HALL

Chairs: Joaquim Fernandez-Sola, Spain
Felix Stickel, Switzerland**S24 Neuroimaging Consortia in Alcohol Research
(SYMPOSIUM ORGANIZED BY ISBRA-ESBRA)**

DANAE HALL

Chairs: Rainer Spanagel, Germany
Mickael Naassila, France

10:00 - 10:45

Lecture Nordmann Award 2016 Winner

MINOS HALL

Chair: Philippe de Witte
Lucia Hipólito, Spain

10:45 - 11:45

PLENARY7 Chair: Felix Stickel

**Alcohol-related liver disease and its neurological
co morbidities—is it all in the genes**

Marsha Y Morgan, UK

11:45 - 13:00

CLOSING CEREMONY, AWARDS



ESBRA CRETE 2017 SCIENTIFIC PROGRAM

SCIENTIFIC PROGRAM

OCTOBER

SUNDAY 8TH

MONDAY 9TH

TUESDAY 10TH

WEDNESDAY 11TH

SUNDAY 8TH OCTOBER, 2017

10:00 - 13:30 Registrations - Olympus Hall

11:00 - 13:00**APHRODITE HALL****ESBRA Board Meeting 1****13:00 - 14:30****DANAE HALL****FREE ORAL COMMUNICATIONS PRECLINICAL-CNS-PSYCHOSOCIAL****Chairs: Roberta Ward, Belgium/UK / Consuelo Guerri, Spain**

A structural and functional study of the effects of rs698 (Ile350Val) and rs1693482 (Arg272Gln) in ADH1C / *Z. Alsafi, UK*

Corticosteroid modulation and testosterone changes during alcohol intoxication affects voluntary alcohol drinking / *P. Eriksson, Finland*

The methodology of Clubs of Alcoholics in Treatment in the framework of systemic therapy / *I. Anifantakis, Italy*

Effect of Screening and Brief Interventions (SBI) in reducing the risk drinking by individuals with HIV / *T. Barroso, Portugal*

Low μ -opioid receptor status in alcohol dependence identified by combined positron emission tomography and post-mortem brain analysis / *D. Hermann, Germany*

Identification of at-risk alcohol consumption patterns: retrospective surveys versus a smartphone application / *A. Poulton, Australia*

Assessment of sleep - wake patterns in Lesch's type 1 and type 2 tobacco dependents / *N. Souirti, Austria*

ATHENA HALL**FREE ORAL COMMUNICATIONS EPIDEMIOLOGY-PSYCHOSOCIAL****Chairs: Sonya Toteva, Bulgaria / Marcin Wojnar, Poland**

Alcohol beverage household expenditure, taxation and government revenues in broader European WHO region / *M. Jakovljevic, Serbia*

Increases in alcohol use, high-risk drinking and DSM-IV alcohol use disorders in the United States, 2001-2002 and 2012-201 / *B. Grant, USA*

Validity and cultural characteristics of Lesch alcoholism typology in a Bulgarian sample / *V. Jenkov, Bulgaria*

Binge-drinking and risky alcohol consumption among university students. / *L. Moure-Rodriguez, Spain*

Alcohol drink advertisement analysis and Hellenic and European legislation regulations compliance investigation / *A. Simotas, Greece*

A diet high in ω 6 polyunsaturated fatty acids leads to liver injury that was attenuated by decreased ω 6: ω 3 ratio in a drinking in the dark mouse model / *I. Kirpich, USA*

14:30 - 15:30**PLENARY1 Chair: Esa Korpi, Finland**

Ethanol's interaction with brain dopamine systems provides clues for new treatments of alcoholism
Bo Söderpalm, Sweden

SUNDAY 8TH OCTOBER, 2017**15:30 - 16:00****COFFEE TO GO****16:00 - 17:30****MINOS HALL****S01 Alcoholic fatty liver: Pathology and screening strategies****Chairs: Sebastian Mueller, Germany / Claus Hellerbrand, Germany**

Alcohol and Obesity: a dangerous association for fatty liver disease
Claus Hellerbrand, Germany

Controlled attenuation parameter- a novel way to measure fatty liver
Magali Sasso, France

Controlled attenuation parameter (CAP) accurately diagnoses hepatic steatosis in patients with alcoholic liver disease / *Maja Thiele, Denmark*

Delayed resolution of liver stiffness and steatosis after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M / *Sebastian Mueller, Germany*

DANAE HALL**S02 Acute and chronic effects of ethanol on ligand-gated ion channels****Chairs: Luis G. Aguayo, Chile / Mia Ericson Sweden**

Role of glycine receptors in ethanol consumption behavior
Mia Ericson, Sweden

Persistent neuroplasticity in VTA DA neurons induced by alcohol and GABAergic drugs
Esa Korpi, Finland

The presence of glycine receptors in different brain regions can explain the different effects of ethanol / *Luis G. Aguayo, Chile*

ATHENA HALL**WORKSHOP 1****Human error, medical error and how they are built***Anthony Kogevinas, Greece / Nurdan Tözün, Turkey***17:30 - 18:30****PLENARY2 Chair: Iannis Mouzas, Greece****Pharmacological treatment of alcoholic patients: a focus on GABA_B-ergic drugs***Giovanni Addolorato, Italy***18:30 - 19:30****OPENING CEREMONY / WELCOME SPEECHES****OPENING SPEECH****Spinalonga, a monument of outstanding universal value***Nick Panoutsopoulos, archaeologist***19:30****Exhibition opening & Get together - welcome reception - ALCOHOL FREE COCKTAILS**

MONDAY 9TH OCTOBER, 2017**08:30 - 10:00****MINOS HALL****S03 Investigation of vulnerability to addictive behavior in animal models of alcohol use disorder**
Chair: Mickael Naassila, FranceInteractions between microbiota and alcohol-related behaviors
*José-Antonio Lopez-Moreno, Spain*Social play as a factor for risk or resilience to loss of control over alcohol seeking rats
*Heidi Lesscher, Netherlands*Vulnerability to develop excessive alcohol intake in the post-dependent state model of voluntary binge drinking rats
*Mickael Naassila, France*Effects of energy drinks on alcohol consumption
*Victor Echeverry-Alzate, Spain***DANAE HALL****S04 Role of iron in alcoholic liver disease: Molecular insights and prognostic aspects**
Chairs: Sebastian Mueller, Germany / Carolin Lackner, AustriaHistology of iron overload in alcoholic liver disease: Are there prognostic implications?
*Carolin Lackner, Austria*Iron parameters determine the mortality in alcoholic liver disease.
*Pavel Strnad, Germany*Enterohepatic adaptation of iron transport and metabolism to acute high altitude hypoxia – insights into general principles of iron homeostasis
*Andreas Geier, Germany*Independent and additive induction of hepcidin by hypoxia and peroxide: Evidence for NOX4-mediated iron signaling
*Ines Silva, Portugal*Masked-hemolysis as novel cause of hepatic iron overload in ALD.
*Sebastian Mueller, Germany***ATHENA HALL****WORKSHOP 2****Lesch Typology: How to use it in daily practice***Otto Lesch, Austria***10:00 - 10:30****COFFEE TO GO****10:30 - 11:30****PLENARY3 Chair: Helmut Seitz, Germany**
Alcohol and Cancer: From epidemiology to genetic susceptibility and animal models
Vasilis Vasiliou, USA

MONDAY 9TH OCTOBER, 2017**11:30 - 13:00****MINOS HALL****S05 Drinking to cope or coping not to drink - managing emotions in alcohol dependence****Chairs: Marcin Wojnar, Poland / Kirk J. Brower, USA**

Inter- and intrapersonal emotional processes in treated alcohol-dependent patients and non-addicted healthy individuals

M. Kopera, Poland

Physician drinking and depression

Kirk J. Brower, USA

Alcohol dependence in psychopathy

Aleksandra Krasowska, Poland

Emotion regulation and impulsivity in alcohol-dependent patients

Andrzej Jakubczyk, Poland

DANAE HALL**S06 Modifiers of progression of alcoholic liver disease****Chairs: Claus Hellerbrand, Germany / Felix Stickel, Switzerland**

Effect of iso-alpha-acids, bitter acids in beer, on acute alcohol induced liver injury

Ina Bergheim, Austria

Influence of hepatic preinjury on development of alcoholic liver disease

Steven Dooley, Germany

Effects of the hop flavonoid Xanthohumol on alcohol induced hepatic steatosis, inflammation and fibrosis

Claus Hellerbrand, Germany

Cannabinoid receptors modulate alcohol-induced liver injury

Eleonora Patsenker, Switzerland

ATHENA HALL**S07 Treatment of alcohol dependence with agonistic substances****Chairs: Albrecht Ulmer, Germany / Icro Maremmani, Italy**

Established and future therapies in chronic alcohol dependence

Henriette Walter, Austria

Documented experience with Dihydrocodeine, Buprenorphine, Baclofen and Clomethiazole

Albrecht Ulmer, Germany

GHB as part of agonist treatment when alcohol is a co-dependence

Icro Maremmani, Italy

MONDAY 9TH OCTOBER, 2017**13:00 - 14:00****LUNCH BREAK****14:00 - 14:30****Poster Session I****14:30 - 15:30****PLENARY4 Chair: Jonathan Chick****Alcohol misuse in special populations; learning disabilities and people with traumatic brain injury.***Christos Kouimtsidis, UK***15:30 - 17:00****MINOS HALL****S08 Clinically relevant research in subgroups of alcoholism****Chairs: Roberta Ward, UK/Belgium / Henriette Walter, Austria**Towards personalized treatments for alcohol use disorder: a focus on alpha-1 blockade
*Carolina L. Haass-Koffler, USA*Temperament and motivation in subgroups of alcoholism
*Samuel Pombo, Portugal*The role of microglia in the alcoholic brain
*Roberta Ward, UK and Belgium*Pharmacotherapy in Lesch Alcoholism Typology
*Henriette Walter, Austria*Subgroups of addiction: from basic research to therapy
*Discussant: Otto Lesch, Austria***DANAE HALL****S09 Role of Nutrition in Alcoholic Liver Disease****Chairs: Irina A. Kirpich, USA / Samir Zakhari, USA**

Dietary linoleic acid and its oxidized metabolites exacerbate liver injury caused by ethanol via induction of hepatic pro-inflammatory response.

*Irina A. Kirpich, USA*Role of fat/carbohydrate ratio and dietary fat type in development of alcoholic pathology
*Martin J.J. Ronis, USA*Betaine: A promising therapeutic in the treatment of alcohol-induced liver injury.
*Kusum Kharbanda, USA*Summary and Discussion. Nutrition and alcohol-induced multiorgan pathology: Clinical aspects
Samir Zakhari, USA

MONDAY 9TH OCTOBER, 2017**15:30 - 17:00****ATHENA HALL****S10 Why do repeated alcohol detoxifications matter?****Chairs: Christos Kouimtsidis, UK / Theodora Duka, UK**

Cognitive and psychological impact of alcohol detoxifications
Theodora Duka, UK

Neuro-inflammation and alcohol addiction: correlation with memory and motor impairment
Alexis Bailey, UK

Clinical implications and interventions to reduce the risk of unsuccessful alcohol detoxifications / *Christos Kouimtsidis, UK*

17:00 - 17:30**COFFEE TO GO****17:30 - 19:00****MINOS HALL****S11 Novel G protein-coupled receptors as potential targets for treating alcoholism****Chair: Esa Korpi, Finland**

Introduction: Beyond the opioid receptor antagonists
Esa Korpi, Finland

Novel findings on Nociceptin receptor system as a treatment target for alcoholism
Roberto Ciccocioppo, Italy

Dopamine D3 receptor-dependent changes in GABAA receptor alpha 6 subunit expression control voluntary ethanol intake
Gian Marco Leggio, Italy

Amylinergic receptor activation attenuates alcohol-mediated behaviours in rodents
Elisabet Jerlhag, Sweden

Oxytocin system and alcohol reward: from rodents to man
Rainer Spanagel, Germany

DANAE HALL**S12 Possibilities and pitfalls in mutual help for alcohol problems****Chair: Jonathan Chick, UK**

Learning resilience: exploring recovery in a sample of adherents of the 12 step groups
Claire Hiernaux, France

Mutual-aid associations: a hidden resource to improve knowledge and clinical research on alcoholism / *Bertrand Nalpas, France*

Barriers to professional's usage of mutual aid groups
Jonathan Chick, UK.

How does engagement with online mutual aid support recovery from problematic alcohol use? / *Julia Sinclair, UK*

MONDAY 9TH OCTOBER, 2017**17:30 - 19:00****ATHENA HALL****S23 Alcohol and cancer****Chairs: Vasilis Vasiliou, USA / Helmut K. Seitz, Germany**

Alcohol and cancer risk with focus on moderate drinking
Carlo La Vecchia, Italy

Alcohol and cancer: Update 2017
Samir Zakhari, USA

Molecular mechanisms in alcohol-induced cancer: Novel implications for acetaldehyde and lipid peroxidation aldehydes
Vasilis Vasiliou, USA

Alcohol and fat: A double whammy for liver injury and cancer
Devanshi Seth, Australia

The role of CYP2E1 in alcoholic liver disease and alcohol mediated hepatocarcinogenesis
Helmut K. Seitz, Germany

19:00 - 20:30**DANAE HALL****ESBRA General Assembly**

TUESDAY 10TH OCTOBER, 2017**08:30 - 10:00****MINOS HALL****S13 Challenges in the treatment of alcoholic liver disease
(Symposium organized by the Hellenic Association for the Study of the Liver)****Chair: Evangelos Akriavidis, Greece**

Treatment strategies and optimal therapeutic interventions in acute alcoholic steatohepatitis
Alexandra Alexopoulou, Greece

Current views on pentoxifylline issue for acute alcoholic steatohepatitis
Dimitrios Samonakis, Greece

Succeeding alcohol abstinence: A hard issue?
Mairi Koulentaki, Greece

Liver transplantation in alcoholic liver disease: Pros & Cons
Emmanouil Sinakos, Greece

DANAE HALL**S14 New approaches for understanding alcohol use disorders and potential new treatments (ESBRA-LASBRA Joint Symposium)****Chairs: Rosana Camarini, Brazil / Mickael Naassila, France**

Understanding the neurobiology of alcohol abstinence: The oxytocin story
Alexis Bailey, UK

Parallel approaches for oxytocin and environmental enrichment upon ethanol's rewarding effects
Rosana Camarini, Brazil

Individual variation in the susceptibility to loss of control over alcohol use in rats
Heidi Lesscher, The Netherlands

Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration in alcohol dependent and non-dependent rats
Mickael Naassila, France

ATHENA HALL**WORKSHOP 3****Benefits of hypnotherapy against craving?***Henriette Walter, Austria***10:00 - 10:30****COFFEE TO GO****10:30 - 11:30****PLENARY5 Chair: Giovanni Addolorato****Subgroups of addiction: From basic research to therapy***Otto Lesch, Austria*

TUESDAY 10TH OCTOBER, 2017**11:30 - 13:00****MINOS HALL****S15 New insights into adolescent binge drinking: Preclinical and clinical studies****Chairs: Consuelo Guerri, Spain / Rosana Camarini, Brazil**

Neuroinflammation and epigenetic processes after only two binges of ethanol in young adult rats / *Olivier Pierrefiche, France*

Sex differences in peripheral and brain inflammation in adolescents with binge drinking: Preclinical and clinical studies / *Consuelo Guerri, Spain*

Episodic memory in young binge drinkers: A neuropsychological approach
Carina Carbia, Spain

Effects of environmental enrichment upon ethanol-induced conditional place preference and BDNF levels in adolescent and adult mice
Rosana Camarini, Brazil

DANAE HALL**S16 Alcoholic Fatty Liver Disease: Use of animal and cell models for identification of potential novel therapeutic targets and implications of alcohol-therapeutic interactions****Chairs: Carol A. Casey, USA / Min You, USA**

Role of matrix rigidity on hepatocytes and liver sinusoidal endothelial cells in alcohol induced hepatic fibrogenesis
Srivatsan Kidambi, USA

MitoNEET deficiency stimulates endocrine adiponectin-Fgf15/19 signaling and alleviates alcoholic steatohepatitis in mice. / *Min You, USA*

Ethanol-induced disorganization of Golgi apparatus: Role of defective Rab3D function
Carol A. Casey, USA

Drug of use interaction with alcohol-induced liver injury
Manuela Neuman, Canada

ATHENA HALL**S17 Alcohol use disorders in the General Hospital****Chairs: Ioannis Diakogiannis, Greece / Panagiotis Panagiotidis, Greece**

Management of alcoholic patients in the emergency department: Physical and psychiatric problems
Ioanna Myta, Greece

Screening and brief interventions for alcohol use disorders in a General Hospital setting
Panagiotis Panagiotidis, Greece

Liaison services for alcohol use disorders in the General Hospital
Konstantinos Randis, Greece

Group therapy for alcohol use disorders in a General Hospital setting
Ioannis Diakogiannis, Greece

TUESDAY 10TH OCTOBER, 2017**13:00 - 14:00****LUNCH BREAK****14:00 - 14:30****Poster Session II****ATHENA HALL****ESBRA BOARD MEETING II****14:30 - 15:30****MINOS HALL**

PLENARY6 Chair: Consuelo Guerri
Fetal Alcohol Spectrum Disorders (FASD). An overview
Edward P. Riley, USA

15:30 - 17:00**MINOS HALL**

S18 Joint EASL-ESBRA symposium
New molecular insight leads to new therapeutic concepts
Chairs: Pau Sancho-Bru (EASL) / Felix Stickel (ESBRA)

MicroRNAs in alcoholic hepatitis – markers or targets, or both?
Pau Sancho-Bru, Spain

Alcohol withdrawal and hepatic encephalopathy in people
 with cirrhosis - a therapeutic dilemma
Marsha Y. Morgan, UK

How to diagnose and treat safely alcohol dependence in patients with alcoholic
 liver disease?
Marcin Wojnar, Poland

Applying genetic information on hepatocellular carcinoma surveillance
 strategies – are we there yet?
Luca Valenti, Italy

TUESDAY 10TH OCTOBER, 2017**15:30 - 17:00****DANAE HALL****S19 Alcohol use disorders in Greece: Clinical and treatment issues****Chairs: Thomas Paparrigopoulos / Dimos Fotopoulos**

Alcohol use disorders and co-occurring psychopathology: Clinical issues and strategies
Eleftherios Mellos, Greece

Alcohol treatment modalities: the Greek experience. The "Athena" Unit paradigm
Dimitrios Panteleakis, Greece

Alcoholology Outpatient Clinic in a University Hospital. Aspects of an interdisciplinary approach
Evangelos Grinakis, Greece

Treatment of alcohol use disorders in an inpatient setting: Clinical issues and management
Thomas Paparrigopoulos, Greece

Priorities and concerns on alcohol use in Europe and Greece.
Dimos Fotopoulos, Greece

ATHENA HALL**S20 Alcohol potentiates the pathogenesis of viral infections****Chairs: Kusum K. Kharbanda, USA / Natalia A. Osna USA**

Alcohol potentiates viral hepatitis progression: Role of apoptotic bodies
Natalia A. Osna, USA

Epigenetic mechanisms in alcohol and HIV-infection associated immune suppression
Shirish Barve, USA

Alcohol interaction with HIV disease pathogenesis; translational approach to understanding mechanisms and comorbidities
Patricia E. Molina, USA

Alcoholic liver disease and hepatitis C
Sebastian Mueller, Germany
Discussant: *Samir Zakhari, USA*

16:00 - 17:00**COFFEE TO GO****17:00 - 18:00**

Charles Lieber Memorial Lecture Chair: Tomas Zima
Alcohol Intake: From Initiation to Relapse Binge-drinking.
Mechanisms and Translational Opportunities

Yedi Israel, Chile

TUESDAY 10TH OCTOBER, 2017**18:00 - 19:30****MINOS HALL****S21 Comorbidities of alcohol dependence****JMSAAS/ESBRA joint symposium****Chairs: Toshi Saito, Japan / Helmut K. Seitz, Germany**

The role of class III alcohol dehydrogenase in alcohol-related disorder on liver and bone
Takahisa Okuda, Japan

Survey of the relationship between alcohol - related cognitive dysfunction and cerebral blood flow
Tomohiro Shirasaka, Japan

Comorbidities of alcoholics with homozygous for the aldehyde dehydrogenase 2*2 gene allele
Fumihiko Ueno, Japan

Alcohol misuse in combination with drug therapy. A deadly combination
Manuela Neuman, Canada

Hypoxia induced hepcidine: role of STAT3 in the liver
Ines Silva, Germany

DANAE HALL**S22 YOUNG INVESTIGATOR SYMPOSIUM****Chairs: Tomas Zima, Czech Republic / Iannis Mouzas, Greece**

Insights into the mechanisms underlying the relationship between stress and alcohol consumption
Sebastian Trautmann, Germany

Non-alcoholic hepatic steatosis and liver features among patients with chronic hepatitis B
Nazlı Begüm Öztürk, Turkey

Changes in the serum metabolite profile correlate with reduced brain grey matter volume in heavy-drinking young adults
Olli Kärkkäinen, Finland

Moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline
Anya Topiwala, UK

ATHENA HALL**WORKSHOP 4****Cognitive behavioral treatment in alcohol use disorders. A user guide***Christos Kouimtsidis, UK***20:30**

Departure by coach in front of the Creta Maris Convention Centre
Evening including dinner arrangements and a Folklore show in a Cretan Village
Return to the hotel around Midnight

WEDNESDAY 11TH OCTOBER, 2017**08:30 - 10:00****MINOS HALL****FREE ORAL COMMUNICATIONS / ALCOHOL INDUCED ORGANIC DAMAGE****Chairs: Joaquim Fernandez-Sola, Spain / Felix Stickel, Switzerland**

Stressful exposure to the public in the workplace is associated with alcohol use: findings from the Constances cohort / *G. Airagnes, France*

Alcohol consumption during pregnancy and lactation in rats affects the postnatal development of cerebellum cortex in their offspring / *P.A. Sukhadolski, Belarus*

Organ and sex specific effect of chronic alcohol consumption on plasmacytoid dendritic cells / *C. Aloman, USA*

Carriage of rs738409 in PNPLA3 is positively associated with the severity of histological damage in patients with alcoholic hepatitis / *S.R. Atkinson, M.Y. Morgan, UK*

Decreased $\omega 6:\omega 3$ ratio or resolvin D1 treatment attenuated chronic alcohol-induced liver injury in mice via reducing hepatic neutrophil infiltration and down-regulation of pro-inflammatory gene expression / *I.Kirpich, USA*

Development of a peripherally restricted CB1 receptor antagonist for alcoholic steatosis / *R. Maitra, USA*

DANAE HALL**S24 Neuroimaging Consortia in Alcohol Research / (SYMPOSIUM ORGANIZED BY ISBRA-ESBRA)****Chairs: Rainer Spanagel, Germany / Mickael Naassila, France**

The ICCAM platform: To investigate the neuropharmacology of brain processes relevant to addiction / *George Savulich, UK*

The SyBil-AA project: Modeling and validating disease state networks in human and animal brains / *Wolfgang Sommer, Germany*

IMAGEN: Determinants of early alcohol use in healthy adolescents / *Frauke Nees, Germany*

National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA). Determinants of problematic alcohol use on the developing adolescent brain / *Bonnie J. Nagel, USA*

10:00 - 10:45**MINOS HALL****Lecture Nordmann Award 2016 Winner****Chair: Philippe de Witte***Lucia Hipólito, Spain***10:45 - 11:45****MINOS HALL****PLENARY7 Chair: Felix Stickel****Alcohol-related liver disease and its neurological co morbidities—is it all in the genes***Marsha Y Morgan, UK***11:45 - 13:00****CLOSING CEREMONY, AWARDS**



ESBRA CRETE 2017 SCIENTIFIC PROGRAM

PLENARY

OCTOBER

SUNDAY 8TH

MONDAY 9TH

TUESDAY 10TH

WEDNESDAY 11TH

PLENARY 1

ETHANOL'S INTERACTION WITH BRAIN DOPAMINE SYSTEMS PROVIDES CLUES FOR NEW TREATMENTS OF ALCOHOLISM.

Bo Söderpalm

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg

Animal and human studies have revealed that ethanol activates brain dopamine neurons resulting in dopamine release in striatal areas, most notably in the nucleus accumbens (nAc; ventral striatum). Further, repeated exposure to alcohol reduces baseline extracellular dopamine levels in rats and brain imaging studies in alcoholics suggest that alcoholism, like other substance addictions, is associated with signs of compromised pre- and post-synaptic dopamine activity in the striatum.

In a series of rat studies we have identified that strychnine-sensitive glycine receptors in the nAc and nicotinic acetylcholine receptors in the ventral tegmental area are involved in a neurocircuitry mediating the dopamine activating effect of ethanol and that interference with either receptor population modulates ethanol consumption. Proof for the nicotinic receptor concept was recently obtained in two RCTs studying the partial nicotinic acetylcholine receptor agonist varenicline.

Both studies were positive and the effect sizes were 0.35-0.4, i.e. approximately double those of naltrexone and acamprosate. A theoretical rationale for a new RCT aimed at boosting the varenicline effect will be provided. Also the glycine receptor concept was recently challenged in an RCT with a glycine reuptake blocker. This study was negative, tentatively due to shortcomings in the design, including lack of an objective marker of alcohol intake.

Since animal studies have shown that acamprosate's ethanol intake reducing effect involves glycine receptors, the established clinical effect of acamprosate may, however, serve as proof-of-concept for the glycine receptor concept.

PLENARY 2

PHARMACOLOGICAL TREATMENT OF ALCOHOLIC PATIENTS: A FOCUS ON GABA_B-ERGIC DRUGS

Giovanni Addolorato

Alcohol Use Disorder Unit, Department of Internal Medicine,
Gastroenterology and Hepatology, Catholic University of
Rome, Italy.

In addition to psychosocial intervention, pharmacological approaches represent an effective strategy in the treatment of Alcohol Use Disorders (AUDs). Among effective drugs useful in the treatment of AUD, GABA_B-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present lecture will be focused in particular on the role of Sodium Oxybate (SO) and baclofen.

SO is able to suppress alcohol withdrawal syndrome (AWS), with an efficacy similar to that of diazepam, chlormethiazole and oxazepam, and to prevent relapse. Several studies have shown that SO 50-100 mg/kg, in 3 daily administrations, reduces the number of daily drinks and alcohol craving, and improves the abstinence rate. Non-responders benefited from a divided dosing schedule. Craving for SO with consequent abuse during treatment ranged from 2.6% to 10.1%. Pharmaco-surveillance indicates that SO has limited abuse potential in a clinical setting under strict medical surveillance.

Baclofen was initially investigated in Italy as a possible drug for the treatment of AUD. Preliminary open label and double blind studies showed the efficacy of baclofen to induce and maintain alcohol abstinence at the low dose of 10 or 20 mg. t.i.d. The usefulness of baclofen was subsequently supported in particular in France by several case reports, case series and observational studies in which higher dose was used. These preliminary observations were confirmed in a recent RCT which showed the efficacy and safety of individually titrated high-dose baclofen (30-270 mg/die). The mean dose of baclofen consumed by patients was 180 mg/day. The drug was well tolerated and no serious adverse events were reported. Recently baclofen was approved in France for the treatment of AUD patients with a temporary permission (3 years).

Moreover, baclofen has been found to suppress AWS with an efficacy comparable to that of diazepam. The most interesting aspect of this drug is the safety and effectiveness in patients with advanced liver disease. In view of its primary renal metabolism and the very low liver metabolism (about 15 %), at present baclofen represents the only anticraving medication formally tested in a RCT in AUD patients with liver cirrhosis. In view of its efficacy and safety, baclofen was included both in the European (EASL) and in the American (AASLD) Association for the Study of Liver Diseases clinical practice guidelines for the management of alcoholic liver disease.

PLENARY 3

ALCOHOL AND CANCER: FROM EPIDEMIOLOGY TO GENETIC SUSCEPTIBILITY AND ANIMAL MODELS

Vasilis Vasiliou

Department of Environmental Health Sciences, Yale
School of Public Health, Yale School of Medicine, New
Haven, CT 06520

Alcohol consumption is the third leading risk factor for disease and mortality in Europe. It has also been associated with cancers of the oral cavity, pharynx, larynx, esophagus, liver, colorectum and female breast wherein, a dose-response relationship appears to exist such that the risk of developing these cancers increases in proportion to the amount of alcohol consumed. Enigmatically, alcohol intake decreases the risk of thyroid cancer and lung cancer (with evidence most strongly supporting lower risk for light and moderate drinkers relative to non-drinkers) and does not appear to affect prostate cancer incidence.

Based on these epidemiological data, it is clear that alcohol affects various tissues of the body differently. Human genetic polymorphisms appear to play a role in the interplay between gene-alcohol interactions in cancer outcomes, particularly as they apply to alcohol metabolizing enzymes or enzymes involved in folate synthesis. Research into the mechanisms by which ethanol induces cancer is limited by the lack of an animal model in which alcohol alone is able to induce cancer.

This lecture will address the topic of alcohol and cancer and will focus on the controversies in epidemiological studies, the identification of susceptible populations, and the current status of animal models to study the causal effect of alcohol and cancer.

PLENARY 4

ALCOHOL MISUSE IN SPECIAL POPULATIONS; LEARNING DISABILITIES AND PEOPLE WITH TRAUMATIC BRAIN INJURY

Christos Kouimtsidis

Imperial College London, Surrey and Borders Partnership
NHS Foundation Trust

There is little and conflicting evidence on the prevalence of alcohol misuse and treatment available for people with Intellectual Disabilities (also referred as Learning Disabilities). It is hypothesised though that similarly to other vulnerable populations following the closure of long-stay hospitals, adults with ID have increasingly lived more independently in the community, which has increased their exposure to environmental stressors and alcohol misuse. The session is based on the experience gained from the first in the UK feasibility study on this topic.

Those that sustain Traumatic Brain Injuries are widely recognised to be underserved by current clinical services. Each year an estimated 1 million people attend hospital emergency departments in the UK following TBI, and chronic psychiatric, behavioural and cognitive difficulties are common. There is a well-established link between TBI and alcohol misuse, with both TBI leading to increased levels of alcohol misuse and alcohol misuse contributing to risk of TBIs. The effects of neuronal damage have been shown to increase after TBI accompanied by alcohol intoxication, making this a pressing and timely topic for discussion.

PLENARY 5

SUBGROUPS OF ADDICTION: FROM BASIC RESEARCH TO THERAPY

Otto Michael Lesch

Medical University Vienna, Psychiatric Department
otto.lesch@meduniwien.ac.at

Changes of DSM 5 and ICD 11 show that craving is the central symptom of addiction often independent of the leading drug of addiction.

The etiology in the past was often reduced to the effects of drugs like nicotine or alcohol, but today we know that genetic, biological and psychosocial vulnerabilities are very important to develop addiction.

In trials with nearly 8000 young people we could show the importance of personality factors like temperament or ADHD. The heterogeneity of addiction is undoubted and genetic, basic research and therapeutic trials will be shown demonstrating that we need subgroups of addiction to get better prevention and treatment programs.

These scientific results should be included in a program following the knowledge of psychotherapy in motivation, crisis intervention and relapse prevention programs. WHO and UNDOC published in 2016 the "Minimal Standards of Addiction treatment". It should be our goal to combine scientific data with this minimal standards.

PLENARY 6

FETAL ALCOHOL SPECTRUM DISORDERS: AN OVERVIEW AND UPDATE

Edward P. Riley

San Diego State University, San Diego, CA, USA

The impact of prenatal alcohol exposure is a global public health issue, with an estimated 119,000 children born worldwide every year with fetal alcohol syndrome (FAS). Considering the full spectrum of effects (fetal alcohol spectrum disorders (FASD)) we may be talking about over a million individuals impacted by prenatal alcohol exposure each year. The economic cost of dealing with FASDs is enormous. For example, in Canada FASD was estimated to cost approximately \$1.8 billion per year. Despite campaigns to promote awareness of FASDs, a global prevalence of alcohol consumption during pregnancy is estimated to be near 10%.

This plenary will begin with a short overview of epidemiological and economic data related to FASDs, followed by a discussion of the diagnosis of the various categories included under the umbrella of FASDs. Next will be an overview of recent advances in diagnosis and screening of FASD with an emphasis on novel techniques to overcome the issue of limited access to appropriate diagnostic services. At the core of the health issues related to FASD are the behavioral problems and the next part of this plenary will deal with alterations in brain and behavior with an emphasis on longitudinal changes.

Remaining research challenges, such as the identification of biomarkers and genetic risk/resiliency factors will be addressed in closing.

PLENARY 7

ALCOHOL-RELATED LIVER DISEASE AND ITS NEUROLOGICAL COMORBIDITIES-IS IT ALL IN THE GENES

Marsha Y Morgan

UCL Institute for Liver & Digestive Health,
Division of Medicine, Royal Free Campus,
University College London, Hampstead, London NW3 2PF,
UK marsha.morgan@ucl.ac.uk

Alcohol dependence is a familial disorder and hence genetic factors are thought to play a role in its development. However, the results of a large number of genome-wide association studies have failed to identify robust, replicable candidate genes that confer risk although the protective effect of carriage of variants in ADH1B has been repeatedly confirmed. Alcohol misuse is associated with thiamine deficiency and the development of Wernicke's encephalopathy; variants in the genes responsible for modifying intracellular thiamine transport are associated with the risk for developing this neuropsychiatric condition.

Approximately 20% of individuals who chronically misuse alcohol will develop alcohol-related cirrhosis; this susceptibility is known to be, at least in part, genetically determined. Variants in PNPLA3, TM6SF2 and MBOAT7 account for approximately 35% of the variance.

The presence of cirrhosis is associated with the development of a hepatic encephalopathy which manifests as a wide spectrum of neuropsychiatric abnormalities; patients who are long-short heterozygotes for a promoter microsatellite variant in GLS1 are significantly protected against the development of this syndrome.

CHARLES LIEBER MEMORIAL LECTURE

ALCOHOL INTAKE: FROM INITIATION TO MAINTENANCE AND RELAPSE BINGE-DRINKING. MECHANISMS AND TRANSLATIONAL OPPORTUNITIES.

1 Yedy Israel, 1 María Elena Quintanilla, 1,2 Paola Morales,

3 Marcelo Ezquer 1 Mario Herrera-Marschitz, 3 Fernando Ezquer.

1 Molecular & Clinical Pharmacology Program, ICBM and 2 Department of Neuroscience,
Faculty of Medicine University of Chile, 3Center for Regenerative Medicine,
Faculty of Medicine-Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.

The progression from; (i) initial ethanol intake, to (ii) chronic ethanol intake (without overt intoxication and negative reinforcement) and (iii) relapse-like drinking, can be mechanistically distinguished as separate entities in preclinical studies. (i) Drug studies have shown that ethanol metabolism into acetaldehyde by brain catalase is required to elicit early intake of ethanol. Further, early ethanol intake and dopamine release were fully abolished by blockade (shRNA) of catalase synthesis at the ventral-tegmental-area. Acetaldehyde trapping agents or gene-induced (Aldh2) degradation of acetaldehyde also inhibited early ethanol intake up to 90%. Brain acetaldehyde reacts with dopamine forming salsolinol that has motivational effects per se, which may constitute or may add to the reinforcing effect of acetaldehyde. (ii) Conversely, after chronic voluntary ethanol intake, a reduction of acetaldehyde generation or of acetaldehyde levels no longer influence chronic ethanol intake, whether determined in operant conditions or by voluntary intake. Neuroinflammation generated by chronic ethanol intake appears responsible for the protracted ethanol intake during the chronic maintenance phase. Neuroinflammation per se has been shown to reduce the levels of the astrocyte glutamate transporter (GLT-1), to markedly increase extracellular glutamate levels and to induce astrocyte reactivity. On the ethanol maintenance phase, intake is inhibited by 75-80% by (a) the administration of a cephalosporin antibiotic (Ceftriaxone) that increases GLT-1 gene expression; (b) the administration of an anti-inflammatory drug (N-Acetyl Cysteine) or (c) the intracerebro ventricular injection of anti-inflammatory mesenchymal stem cells. (iii) Following chronic ethanol intake, if animals are deprived of ethanol for a long period (often 14 days), are subsequently exposed to ethanol cues and are allowed ethanol re-access, a marked relapse-like intoxicating ("binge") intake occurs (termed the Alcohol-Deprivation-Effect: ADE). After ethanol deprivation, brain acetaldehyde is again required to elicit the ADE, while neuroinflammation is perpetuated. The ADE is inhibited by 70-85% by anti-catalase shRNA, the intracerebral administration anti-inflammatory mesenchymal stem cells or orally administered N-Acetyl Cysteine. Overall, studies indicate that the administration of (i) oral N-Acetyl Cysteine and (ii) anti-inflammatory mesenchymal stem cells (see also Morales et al ESBRA 2017) afford translational opportunities for the treatment of alcohol-use disorders.

FONDECYT #1170712; #1150589, CONICYT #21130739.



ESBRA CRETE 2017 SCIENTIFIC PROGRAM

POSTER

OCTOBER

SUNDAY 8TH

MONDAY 9TH

TUESDAY 10TH

WEDNESDAY 11TH

POSTERS

PO 01

Alcohol consumption during pregnancy in rats induces dramatic ultrastructural disturbances in brain cortex neurons in offspring

Zimatkin SM, Bon El
Grodno State Medical University, Grodno, Belarus

PO 02

VGLUTs in the mesocorticolimbic brain of adolescent outbred rats exposed to alcohol and nicotine

Vrettou M¹, Nordenankar K^{2#}, Segerström L^{2#}, Wallén-Mackenzie Å³, Fredriksson R², Comasco E^{1*}, Nylander I^{2*}

#*equal contribution

¹Department of Neuroscience, Uppsala University, Uppsala, Sweden, ²Department of Pharmaceutical Bio sciences, Uppsala University, Uppsala, Sweden ³Department of Organismal Biology, Uppsala University, Uppsala, Sweden

PO 03

MAOA methylation: a molecular mechanism behind the effect of early life stress and voluntary alcohol consumption on MAOA expression in wistar rats

Bendre MN¹, Nilsson KW², Granholm L³, Nylander I³, Comasco E¹

¹Department of Neuroscience, Uppsala University, Uppsala, Sweden, ²Centre for Clinical Research, Uppsala University, Västerås, Sweden, ³Department of Pharmaceutical Biosciences, Uppsala, Sweden

PO 04

Anti-inflammatory mesenchymal stem cell-derived spheroids inhibit chronic and relapse-like ethanol intake and reduce oxidative stress

^{1,2}Morales P, ³Ezquer F, ²Quintanilla ME,

²Lespay-Rebolledo C, ³Santapau D,

¹Valdes JL, ⁴Kogan M, ⁴Salas E, ²Herrera-Marschitz M, ²Israel Y.

¹Department of Neuroscience, ²Molecular and Clinical Pharmacology Program, ICBM; Faculty of Medicine; ⁴Department Pharmacol Toxicol Chem, University of Chile; ³Center for Regenerative Medicine, Faculty of Medicine-Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.

PO 05

UChB Fenofibrate-induced reduction of voluntary ethanol intake in uchb rats: evidence of peripheral and central effects

Rivera-Meza M¹, Jerez E¹, Muñoz D², Quintanilla ME³, Salinas-Luypaert C¹, Fernández K⁴, Karahanian E^{2,5}

¹Department of Pharmacological and Toxicological Chemistry, Universidad de Chile, Santiago, Chile, Center for Biomedical Research, Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile, ³Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile, ⁴CIB, Faculty of Health and Dentistry, Universidad Diego Portales, Santiago, Chile, ⁵Research Center for the Study of Alcohol Drinking Behavior in Adolescents, Universidad Autónoma de Chile, Santiago, Chile

PO 06

Limbic neuroadaptations may contribute to enhanced skilled reach performance following repeated ghrelin administration

Vestlund J¹, Bergquist F¹, Eckernäs D¹, Engel JA¹, Licheri V², Adermark L², Jerlhag E¹

¹Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

²Addiction Biology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

PO 07

Cannabinoid CB2 receptors drive alcohol seeking and relapse in conditioned place preference procedure

Warnault V¹, Mondragón N¹, Pastor A², De La Torre R^{2,3}, Valverde O^{1,4}

¹Research Group in Neurobiology of Behaviour (GReNeC-NeuroBio), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra, Barcelona, Spain, ²Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain, ³Department of Experimental and Health Sciences (DCEXS), Pompeu Fabra University (UPF), Barcelona, Spain, ⁴Hospital del Mar Medical Research Institute, Barcelona, Spain

POSTERS

PO 08

Alcohol use among epileptics in dry vs. wet Native Alaskan villages: does prohibition work?Jeng, G¹, Hines, S²¹Center for Neuroscience, University of California Davis, USA, ²Alaska Native Medical Center, Anchorage, Alaska, USA

PO 09

Higher follicle stimulating hormone plasma levels differentiate alcoholic males from matched controlsKarpyak VM¹, Winham SJ¹, Ho (Ada) MC¹
¹Mayo Clinic, Rochester, MN, USA

PO 10

The brain of binge drinkers at rest: resting-state EEG characteristics as assessed by exact low-resolution electromagnetic tomography (eLORETA)López-Caneda E¹, Cadaveira F², Correas A³, Crego A¹, Maestú F³, Rodríguez Holguín S²¹Neuropsychophysiology Lab, Research Center in Psychology (CIPsi), School of Psychology, University of Minho, Braga, Portugal, ²Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Galicia, Spain, ³Laboratory of Cognitive and Computational Neuroscience, Center for Biomedical Technology (CTB), Madrid, Spain

PO 11

Differences in drinking history between healthy people and patients with cerebral infarctionNishikawa T^{1,2}, Miyamatsu N^{2,3}, Higashiyama A^{2,4}, Hojo M⁵, Nishida Y², Fukuda S⁶, Ichiura K³, Kubo S², Okamura T^{2,7}¹ Faculty of Health Science, Kyoto Koka Women's University, Kyoto, Japan, ² Foundation for Biomedical Research and Innovation, Hyogo, Japan, ³ Department of Clinical Nursing, Shiga University of Medical Science, Shiga, Japan, ⁴ Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Osaka, Japan, ⁵ Shiga Medical Center for adults, ⁶ National Hospital Organization Kyoto Medical Center, ⁷ Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan

PO 12

Evaluation of a cognitive rehabilitation program in 491 patientsPerney P¹, Nalpas B¹, Alarcon R¹, Vial B¹, Robert L¹, Rouch J¹, Legrand T¹, Ewert V¹, Simon N², Donnadiou-Rigole H³, Pelletier S¹
¹Service Addictologie, Hôpital du Grau du Roi, CHU Caremeau, Nîmes, ²APHM, Hôpitaux Sud Sainte Marguerite, Marseille, ³Service de Médecine Interne et Addictologie, Hôpital Saint Eloi, Montpellier

PO 13

White matter anomalies in the inhibitory circuitry of young binge drinkers: a diffusion tensor imaging studySousa S¹, Sampaio A¹, Marques P^{2,3}, Gonçalves O^{1,4,5}, Crego A¹¹Neuropsychophysiology Lab, CIPsi, School of Psychology, University of Minho, Braga, Portugal, ²Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, ³ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal, ⁴Spaulding Neuromodulation Center, Department of Physical Medicine & Rehabilitation, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Charlestown, USA, ⁵Department of Applied Psychology, Bouvé College of Health Sciences, Northeastern University, Boston, USA

PO 14

Total alcohol consumption and hangover severity patternsVan de Loo AJAE^{1,2}, Van Schroyen Lantman M¹, Mackus M¹, Garssen J^{1,3}, Scholey A⁴, Verster J.C.^{1,2,3}¹ Division of Pharmacology, Utrecht University, Utrecht, The Netherlands, ² Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands, ³ Nutricia Research, Utrecht, The Netherlands, ⁴ Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia

POSTERS

PO 15

Mental resilience and hangover severity

Van de Loo AJAE^{1,2}, Van Schrojenstein Lantman M¹, Mackus M¹, Aletta D Kran-eveld^{1,2}, Karel Brookhuis³, Garssen J^{1,4}, Verster J.C.^{1,2,5},

¹Division of Pharmacology, Utrecht University, Utrecht, The Netherlands, ²Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands, ³Groningen University, Groningen, The Netherlands, ⁴Nutricia Research, Utrecht, The Netherlands, ⁵Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia

PO 16

Blood alcohol concentration and memories of faces and scenes in adolescent binge drinkers

Vinader-Caerols C¹, Duque A¹, Monleón S¹
¹Department of Psychobiology, University of Valencia, Valencia, Spain

PO 17

Preliminary results on the implementation of the screening, brief intervention, and referral to treatment (SBRT) approach in a Portuguese Emergency Department

Barroso, T¹, Esgaio T²
¹Health Sciences Research Unit: Nursing; Nursing School of Coimbra, Coimbra, Portugal, ²Health Sciences Research Unit: Nursing, Nursing School of Coimbra, Coimbra, Portugal

PO 18

Drinking behavior among young-, old- and oldest-old in Japan

Miyamatsu N¹, Ogita M¹, Okura M², Yamamoto M³, Nakai T³, Numata T³, Arai H^{2,4}

¹Department of Clinical Nursing, Shiga University of Medical Science, Otsu, Japan, ²Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Kami-cho Municipal Office, Kami, Japan, and ⁴National Center for Geriatrics and Gerontology, Obu, Japan

PO 19

Alcohol consumption and psychological distress in healthy Japanese residents: the Kobe study

Godai K^{1,2,3}, Miyamatsu N^{1,2}, Higashiyama A^{1,4}, Kubo S¹, Nishida Y¹, Sugiyama D^{1,5}, Nii Y^{1,6,7}, Tatsumi Y^{1,8}, Nishikawa T^{1,9}, Okamura T^{1,5}

¹Foundation for Biomedical Research and Innovation, Kobe, Japan, ²Department of Clinical Nursing, Shiga University of Medical Science, Otsu, Japan, ³Department of Health Promotion Science, Graduate School of Medicine, Osaka University, Suita, Japan, ⁴Department of Preventive Medicine and Epidemiology Informatics, National Cerebral and Cardiovascular Center, Suita, Japan, ⁵Department of Preventive Medicine and Public Health, Keio University, Shinjuku, Japan, ⁶Department of Nursing, Shijonawategakuen University, Daito, Japan, ⁷Department of Nursing, Graduate School of Medicine, Shiga University of Medical Science, Otsu, Japan, ⁸Department of Hygiene and Public Health, Teikyo University School of Medicine, Itabashi, Japan, ⁹Department of Health and Nutrition, Kyoto Koka Women's University, Kyoto, Japan

PO 20

Abuse of alcohol by adolescent girls

Kirpichenka AA¹, Kopitov AV², Muzhichenka VA³

¹Vitebsk State Medical University, Vitebsk, Belarus, ²Republican Research and Practice Center for Mental Health, Minsk, Belarus, ³Vitebsk Regional Clinical Center of Psychiatry and Narcology, Vitebsk, Belarus

PO 21

The galician beverage picture set (GBPS): a standardized database of alcoholic and non-alcoholic images

López-Caneda E¹ and Carbia C²
¹Neuropsychophysiology Lab, Research Center in Psychology (CIPsi), School of Psychology, University of Minho, Braga, Portugal, ²Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Galicia, Spain

POSTERS

PO 22

Alcohol consumption and awareness of associated risks among Medical School studentsMyrto Konidaki¹, Vasiliki Georgopoulou¹, Vassilis Valatas², Iannis Mouzas^{1,2}¹Medical School, University of Crete, Greece, ²Gastroenterology Department, University Hospital, Heraklion, Greece

PO 23

Scientific education as a promising tool for addiction prevention in adolescentNalpas B¹, Cordonnier J², Le Bras M², Lafay-dufour F³¹Inserm, Paris, France, ²Association l'Arbre des Connaissances, Paris, France, ³MIL-DECA, Paris, France

PO 24

Attending clubs of alcoholics in treatment enhance adherence and treatment outcome in Alcohol Outpatient ClinicGrinakos E^{1,2}, Koulentaki M^{1,2,3}, Sfakianaki K², Liodaki N^{1,2}, Mouzas I^{1,3}¹Alcohol Outpatient Clinic, University of Crete, Heraklion, Greece, ²NGO "Epistrofi", Heraklion, Greece, ³Gastroenterology Clinic, University of Crete, Heraklion, Greece

PO 25

Fabomotizole effect on pre- and postnatal development and DNA damages in the offspring of rats after ethanol exposure

Durnev AD, Shreder ED

FSBI "Zakusov Institute of Pharmacology", Moscow, Russia

PO 26

Decreased myocardial titin expression in chronic alcoholic cardiomyopathyFernández-Solà J¹ M.D., Toll Argudo M² M.D, Tobías-Baraja E², Moreno-Lozano P.,M.D¹, Garrabou-Tornos G, Ph.D², Guitart-Mampel M², Planavila-Porta A³, Vilarroya F³¹Alcohol Research Unit, Department of Medicine. Hospital Clínic, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona., ²CELLEX Research Laboratory. Department of Medicine, University of Barcelona, Spain, ³ Department of Biochemistry and Molecular Biomedicine, Institut de Biomedicina (IBUB), University of Barcelona, Barcelona, Catalonia, Spain;

PO 27

Effect of moderate beer consumption on the development of non-alcoholic fatty liver disease: studies in miceJung F¹, Lippmann T², Engstler AJ¹, Brandt A¹, Jin CJ², Bergheim, I^{1,2}¹Department of Nutritional Sciences, Molecular Nutritional Sciences, University of Vienna, Vienna, Austria, ²Institute of Nutritional Sciences, S.D. Model Systems of Molecular Nutrition, Friedrich-Schiller-University Jena, Jena, Germany

PO 28

Putative mechanism of electrical myocardium instability in rat model of alcoholic cardiomyopathyKolik LG¹, Roshchevskaya IM², Kozhevnikova LM³, Kryzhanovskii SA¹¹FSBI "Zakusov Institute of Pharmacology", Moscow, Russia, ²Komi Science Centre, Ural Branch of the Russian Academy of Sciences, Syktyvkar, Russia, ³FSBI "Institute of General Pathology and Pathophysiology", Moscow, Russia

PO 29

Wound healing on aged skin of alcoholicsMartinez FE¹, Cassettari LL¹, Nicolau NC¹, Pinheiro PFF¹, Chuffa LGA¹, Padovani CR¹, Martinez M²¹Univ Estadual Paulista, Botucatu, Brasil, ²Univ Federal de São Carlos, São Carlos, Brasil

PO 30

Effects of early postnatal exposure to ethanol causes neuronal loss in cerebral cortexBritton SM¹ and Miller MW^{1,2,3}¹SUNY Upstate Medical University, Syracuse NY, 13210, ²Developmental Exposure Alcohol Research Center, Binghamton, NY 13902, Cortland NY 13045, and Syracuse NY 13210, ³Touro College of Osteopathic Medicine, Middletown NY 10940.

PO 31

The effect of alcohol drinking and smoking on modified atherogenic high density lipoprotein cholesterol levels in a Japanese general populationOkamura T^{1,2}, Sawamura T³, Miura K², Fujiyoshi A², Miyagawa N², Miyamastu N², Ueshima H²¹Keio University School of Medicine, Tokyo, Japan, ²Shiga University of Medical Science, Otsu, Japan, ³Shinshu University, Matsumoto, Japan

POSTERS

PO 32

General Knowledge on alcohol and alcohol use in a cohort of Cretan liver disease patients

Koulentaki M¹, Orfanoudaki E¹, Samonakis D¹, Thalassinos E³, Matrella E¹, Agapitos S², Kalamitsis G², Mouzas I¹

¹Dept of Gastroenterology, University Hospital of Heraklion, ²NGO of Patients with Liver Diseases "Promitheas", Greece, ³Dept of Internal Medicine Venizelion Hospital of Heraklion, Crete, Greece

PO 33

Structural and metabolic disturbances in brain histaminergic neurons following alcohol administration in rats

Phedina K.M., Zimatkin S.M., Paulava D.V. Grodno State Medical University, Grodno, Belarus

PO 34

The effect of orthotopic liver transplantation on miR-21, leptin and gene-methylation patterns in patients suffering from ethyl toxic liver cirrhosis: a pilot study

Proskynitopoulos PJ^{1,6}, Rhein M^{1,5,6}, Jäckel E^{2,6}, Manns MP^{2,6}, Frieling H^{1,5,6}, Bleich S^{1,6}, Thum T^{3,6}, Blüher M⁴, Hillemacher T^{1,6}, Glahn A^{1,6}

¹Department of Psychiatry, Social Psychiatry and Psychotherapy, Hanover Medical School, Hanover, ²Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School, Hanover, ³Institute of Molecular and Translational Therapeutic Strategies, Hanover Medical School, Hanover, Germany, ⁴Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany, ⁵Laboratory of Molecular Neuroscience, Hanover Medical School, Hanover, Germany, ⁶Integrated Research and Treatment Center Transplantation (IFB-Tx)

This work was supported by a grant from the German Federal Ministry for Research and Education (reference number 01EO1302)

PO 35

A natural history study of decompensated alcoholic cirrhosis in Crete. Recent improvement in survival

Samonakis D¹, Koulentaki M¹, Augoustaki A¹, Theodoraki E¹, Orfanoudaki E¹, Tzardi M², Matrella E¹, Kouroumalis E¹, Mouzas I¹

¹Department of Gastroenterology & Hepatology, University Hospital of Heraklion Crete, Greece, ²Department of Histopathology, University Hospital of Heraklion, Crete, Greece

PO 36

Ethanol inhibits IL-2 gene expression in human CD4+ T lymphocytes by decreasing promoter histone H3 phosphorylation: relevance to alcohol induced immune suppression

Smita Ghare, Swati Joshi-Barve, Craig McClain and Shirish Barve

Department of Internal Medicine, Department of Pharmacology and Toxicology, University of Louisville Alcohol Research Center, VA medical center, University of Louisville, Louisville, KY 40202

PO 37

Prognostic value of liver histology in "low-risk" alcoholic liver disease (Maddrey score <32)

Stauber RE¹, Spindelboeck W¹, Rainer F¹, Douschan P¹, Lackner C²

¹Department of Internal Medicine, Medical University of Graz, Graz, Austria, ²Institute of Pathology, Medical University of Graz, Graz, Austria

PO 38

Acrolein, a by-product of alcohol-induced lipid peroxidation, impairs intestinal epithelial barrier function and causes gut permeability

Wei-Yang Chen^{2,3}, Jingwen Zhang^{1,3}, Min Wang^{1,3}, Shirish Barve^{2,3}, Craig McClain^{1,2,3,4} and Swati Joshi-Barve^{1,2,3}


¹Department of Medicine, ²Department of Pharmacology & Toxicology, ³University of Louisville Alcohol Research Center, and ⁴Robley Rex VAMC, Louisville, Kentucky

PO 39

Single cell gene expression analysis identifies a chronic alcohol-mediated shift in the distribution of hepatocyte molecular states after partial hepatectomy

Achanta S¹, Verma A^{1,2}, Hoek JB¹, Vadigepalli R¹

¹Daniel Baugh Institute for Functional Genomics/Computational Biology, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, ²Department of Biomedical Engineering, University of Delaware, Newark, Delaware, USA



Medical Students Committee

Alexandra Fountoulaki
Antonios Kostouros
Christos Tsagkaris
Dimitra Desse
Evangelia Atzoletaki
Evgenia Lymperatou
Marianna Boulkou
Myrto Konidaki
Stefanos Veneris
Theodoros Krasanakis

SPONSORS

abbvie



PARTNERS

EASL, The Home of Hepatology
7 rue Daubin,
1203 Geneva, Switzerland



Charles University
Ovocny trh 3-5,
Prague 1116 36, Czech Republic



CHARLES UNIVERSITY

European Addiction Research
2017 S. Karger AG, Basel

European
Addiction
Research

Municipality of Heraklion



ΠΕΡΙΦΕΡΕΙΑ ΚΡΗΤΗΣ
REGION OF CRETE



University of Crete



ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΡΗΤΗΣ
UNIVERSITY OF CRETE